Meeting Reports and Events
Oligonucleotides: The Next Big Challenge For Analytical Chemistry - George Okafo & Chris Bevan
Sep 13 2010 Read 7318 Times
Research and development of oligonucleotides as therapeutic medicines is experiencing exponential growth and interest within academia, the biotechnology and pharmaceutical industries . This has largely been driven
by several key historical events including:
1. The regulatory approval of the first antisense oligonucleotide (ASO) for cytomegalovirus infection Vitravene® (1998),
2. Approval of Macugen®, an aptamer for treatment of wet macular degeneration (2005) 
3. The discovery by Drs Andrew Fire and Craig Mello of gene silencing by RNA interference (RNAi) (published 1998, Nobel Prize, 2006).
RNAi technology has been used to validate gene targets, and both RNAi and ASO technologies have been used to interfere with targets that are considered non-druggable by traditional small molecule interventions . The early Nobel Prize-winning work by Fire and Mello demonstrated that some genes in C.elegans can be switched off by the introduction of double stranded small interfering RNA (siRNA) to block the normal translation of a specific messenger RNA to the protein product . This early identification of the process has been extended to mammalian cells and the molecular process characterized.
Do you like or dislike what you have read? Why not post a comment to tell others / the manufacturer and our Editor what you think. To leave comments please complete the form below. Providing the content is approved, your comment will be on screen in less than 24 hours. Leaving comments on product information and articles can assist with future editorial and article content. Post questions, thoughts or simply whether you like the content.
In This Edition Articles - Capillary Electrophoresis-Mass Spectrometry for Micro-Metabolomics - Imaged Capillary Iso-Electric Focussing: Background, Status, and Perspectives - High-Throughp...
View all digital editions
Apr 22 2019 Dublin, Ireland
May 13 2019 Fort Worth, Tx, USA
May 17 2019 Shaanxi, China
May 20 2019 Shanghai, China
May 21 2019 Hannover, Germany